Last updated: September 5, 2026
Typhoid Vi polysaccharide vaccine is a mature, low-margin vaccine product with stable demand in international travel, outbreak response and selected public-health programs. Its market position is weakening as typhoid conjugate vaccines, particularly Typbar-TCV, become the preferred product for routine immunization and children. Standalone manufacturer revenue is not publicly reported, but the commercial trajectory is clear: Vi polysaccharide vaccines retain a travel and adult-use niche while losing institutional growth opportunities to conjugate vaccines.
What is the market position of typhoid Vi polysaccharide vaccine?
Vi polysaccharide vaccine is an injectable vaccine containing purified capsular Vi antigen from Salmonella Typhi. It is generally administered as a single dose to adults and children aged two years and older, with revaccination commonly recommended every two years when exposure continues.
The product class has four principal demand segments:
| Segment |
Market role |
Outlook |
| International travelers |
Established use for travelers visiting typhoid-endemic countries |
Stable |
| Outbreak response |
Rapid deployment in exposed populations |
Episodic |
| Adult endemic-country vaccination |
Used where conjugate vaccine access is limited |
Gradually declining |
| Routine childhood immunization |
Increasingly displaced by typhoid conjugate vaccine |
Weakening |
The central commercial issue is product substitution. The World Health Organization recommends typhoid conjugate vaccine, or TCV, as the preferred typhoid vaccine for routine programmatic use because of its effectiveness in young children and longer expected protection. Vi polysaccharide vaccine remains an option where TCV is unavailable or where vaccination is targeted to older populations.[1]
Which companies manufacture typhoid Vi polysaccharide vaccine?
Sanofi’s Typhim Vi is the best-known branded Vi polysaccharide vaccine in developed travel markets. Sanofi markets the product in multiple countries, subject to local approvals and distribution arrangements. Product labeling differs by jurisdiction.
Other Vi polysaccharide products are supplied by manufacturers in India, China and other vaccine-producing countries. Many are sold through government tenders, regional distributors or private travel clinics rather than through globally recognized brands.
The competitive structure is divided:
Branded travel-market suppliers
Sanofi has historically held the strongest branded position through Typhim Vi. The product benefits from physician familiarity, established regulatory approvals and travel-clinic distribution.
Low-cost public-sector suppliers
Manufacturers in emerging markets compete primarily on tender price, production capacity and national regulatory approval. Public-sector purchasing is more price-sensitive than private travel vaccination.
Typhoid conjugate vaccine manufacturers
Bharat Biotech’s Typbar-TCV is the most commercially visible TCV product. It has WHO prequalification and has been used in large-scale introductions in endemic countries. Other TCV developers and manufacturers include Biological E and SK bioscience-related supply networks, depending on market and regulatory status.
TCV is not a direct formulation equivalent to Vi polysaccharide vaccine. It links Vi antigen to a carrier protein, producing a stronger and more durable immune response in young children.
How does Vi polysaccharide vaccine compare with typhoid conjugate vaccine?
TCV has the stronger long-term market profile because it addresses the main limitations of Vi polysaccharide vaccine.
| Attribute |
Vi polysaccharide vaccine |
Typhoid conjugate vaccine |
| Antigen |
Purified Vi capsular polysaccharide |
Vi polysaccharide linked to carrier protein |
| Minimum routine age |
Generally 2 years |
Can be used from 6 months, depending on product |
| Protection duration |
Commonly treated as approximately 2 years |
Longer duration expected; follow-up data continue to mature |
| Booster requirement |
Typically every 2 years for continuing risk |
Product-specific; less frequent boosting expected |
| Routine infant program suitability |
Limited |
Strong |
| WHO program preference |
Secondary option |
Preferred product |
| Travel-clinic use |
Established |
Increasing but less uniform |
| Procurement growth |
Flat to declining |
Stronger |
The shift to TCV is driven by public-health performance rather than by a major manufacturing innovation. Vi polysaccharide vaccine is less suitable for infants, produces limited immunologic memory and requires repeat vaccination. TCV is better aligned with mass vaccination programs that target children in endemic areas.[1]
What is the FDA regulatory status of Typhim Vi?
Typhim Vi is licensed in the United States for active immunization against disease caused by Salmonella Typhi. The product is administered to adults and children two years of age and older. The U.S. prescribing information recommends vaccination at least two weeks before expected exposure and revaccination after two years for individuals who remain at risk.[2]
The vaccine is not approved for children under two years of age. That age limitation reduces its relevance to pediatric routine-immunization programs.
The U.S. market is primarily a travel-vaccine market. The Centers for Disease Control and Prevention recommends typhoid vaccination for travelers visiting areas where typhoid is common, particularly when travel involves smaller cities, rural areas or visits to friends and relatives.[3]
What is the Orange Book status of typhoid Vi polysaccharide vaccine?
The commercial significance of Orange Book-listed patents is limited for Vi polysaccharide vaccine. Typhim Vi is an established vaccine with a long commercial history, and the core composition and manufacturing concepts are old.
No current, high-value exclusivity position comparable to a recently launched biologic is generally associated with the Vi polysaccharide class. Any remaining market protection is more likely to arise from:
- Manufacturing know-how
- Validation history
- Regulatory approvals
- Product-specific supply contracts
- Cold-chain capability
- Brand recognition
- National tender qualification
A detailed Orange Book determination requires review of the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database and the product’s current application records. The commercial market is not materially dependent on a live composition-of-matter patent.
What patents protect typhoid Vi polysaccharide vaccine?
The core Vi antigen technology is mature, and broad foundational patent protection is generally expired or commercially weak. The relevant intellectual-property categories are more likely to include:
Antigen production
Historical patents may have covered bacterial culture, extraction and purification of Vi polysaccharide. These rights are generally old relative to the current product lifecycle.
Purification and conjugation
Purification methods can remain important as manufacturing trade secrets. Conjugation technology is more relevant to TCV products than to unconjugated Vi polysaccharide vaccines.
Formulation and presentation
Potential protection may cover excipients, vial or syringe presentation, stability, container systems and manufacturing controls. Such rights typically have narrower commercial scope than a core vaccine patent.
Manufacturing know-how
The strongest practical barrier is likely process execution. A manufacturer must demonstrate consistency in antigen yield, purity, identity, sterility, potency and lot release. These requirements create regulatory and operational barriers even when patent protection is limited.
When does Vi polysaccharide vaccine lose market exclusivity?
Vi polysaccharide vaccine has already passed the period in which patent exclusivity would normally determine market entry. The product is better characterized as a mature biologic vaccine with regulatory and manufacturing barriers.
Market exclusivity differs by jurisdiction:
| Market |
Primary protection mechanism |
Commercial importance |
| United States |
FDA licensure, manufacturing compliance and brand position |
Moderate |
| European Union |
National or centralized authorization, pharmacovigilance and supply reliability |
Moderate |
| Low- and middle-income countries |
National registration and public tenders |
High |
| Travel clinics |
Brand, availability and physician familiarity |
High |
| UNICEF or government procurement |
WHO prequalification and tender qualification |
Very high |
For this product class, biosimilar rules are not the main competitive framework. A competing Vi polysaccharide vaccine generally requires its own regulatory submission and evidence package. It is not automatically interchangeable with an established product under a conventional small-molecule generic pathway.
Are there Paragraph IV challenges to Vi polysaccharide vaccine?
Paragraph IV litigation is unlikely to be a major current market issue for Typhim Vi. Paragraph IV challenges concern patents listed in the FDA Orange Book and are most relevant when a generic applicant seeks approval before patent expiry.
The Vi polysaccharide vaccine market has a different structure:
- The core technology is mature.
- The leading product has been marketed for decades.
- Competing vaccine manufacturers can pursue independent licensure.
- Manufacturing and clinical comparability requirements are more important than patent invalidity litigation.
- Public-sector buyers often choose among approved products through tenders.
No widely reported, commercially decisive Paragraph IV campaign has reshaped the U.S. Typhim Vi market. The principal competitive threat is substitution by TCV, not an ANDA-driven generic launch.
What is the litigation status for Typhoid Vi polysaccharide vaccine?
There is no widely reported patent litigation campaign currently defining the global Vi polysaccharide vaccine market. Disputes in this category are more likely to involve:
- Supply contracts
- Tender awards
- Product-quality claims
- Regulatory approvals
- Distribution rights
- Trademark or labeling issues
The absence of major patent litigation reflects the age of the technology and the limited value of blocking entry through a core patent. Litigation risk is therefore lower than for newer biologics with active composition, formulation or method-of-use portfolios.
How large is the typhoid Vi polysaccharide vaccine market?
A precise global revenue figure for Vi polysaccharide vaccine is not publicly auditable because manufacturers generally do not report the product as a separate financial segment. Market-research estimates often combine Vi polysaccharide products with TCV, oral typhoid vaccines and broader travel vaccines, making product-specific revenue figures difficult to validate.
The market can be assessed through demand indicators:
| Indicator |
Effect on Vi polysaccharide vaccine |
| International travel |
Supports recurring private-market demand |
| Typhoid incidence in endemic countries |
Supports public-health demand |
| TCV introduction |
Reduces long-term Vi share |
| Government tender pricing |
Compresses margins |
| Outbreaks and humanitarian crises |
Creates short-term volume spikes |
| Travel-clinic adoption |
Preserves branded demand |
| WHO preference for TCV |
Weakens routine-program growth |
WHO estimates that typhoid fever causes millions of illnesses and tens of thousands of deaths annually, with the highest burden in South Asia and other areas with inadequate water and sanitation infrastructure.[1] Disease burden supports vaccine demand, but it does not translate directly into Vi polysaccharide revenue because public programs increasingly procure TCV.
What is the financial trajectory of Vi polysaccharide vaccine?
The financial trajectory is mature-to-declining on a relative basis, with a stable residual business.
Revenue
Revenue is likely concentrated in:
- Private travel vaccination
- Government tenders outside routine TCV programs
- Outbreak-response procurement
- Markets where TCV supply is constrained
The product does not have the growth profile of a newly introduced pediatric vaccine. Volume may remain material while revenue growth stays limited by price competition and substitution.
Pricing
Private travel clinics can support higher prices than public tenders. Public procurement is generally competitive and may prioritize the lowest qualified bid. Branded products can retain pricing power where supply continuity, physician confidence and regulatory history matter.
Margins
Margins are pressured by:
- Mature technology
- Multiple regional suppliers
- Tender competition
- Cold-chain requirements
- Batch-release costs
- Lower utilization outside outbreak periods
Manufacturers with high-volume facilities and integrated distribution have a cost advantage. Small suppliers may struggle when tenders demand large, rapid deliveries.
Capital allocation
Incremental investment is more likely to flow toward TCV, combination vaccines and outbreak-ready manufacturing than toward major expansion of standalone Vi polysaccharide capacity. Vi vaccine capacity remains useful as a lower-cost product and as a supply hedge, but it is less attractive as a long-term growth platform.
What geographic markets remain attractive?
United States and Canada
Demand is concentrated in travelers, military personnel, laboratory workers and other defined risk groups. The market is regulated, recurring and commercially attractive relative to public tenders, but it is limited in size.
Europe
Travel vaccination remains the main commercial channel. Country-specific reimbursement and travel-clinic practices affect volume.
South Asia
The disease burden is high, but routine pediatric demand is moving toward TCV. Vi polysaccharide vaccines may retain a role where price or supply availability prevents immediate TCV adoption.
Sub-Saharan Africa
Public-health demand is growing, but TCV is the favored product for preventive campaigns. Vi polysaccharide vaccine has a secondary role in outbreak response and in settings with limited TCV access.
Latin America
Demand is more fragmented. Travel vaccination, private clinics and national epidemiology determine local opportunity.
What generic launch risks exist for Vi polysaccharide vaccine?
The risk of a conventional generic launch is less important than the risk of multi-source vaccine competition. A new entrant would face:
- Clinical and immunogenicity requirements
- GMP inspection and lot-release obligations
- National registration in each target market
- WHO prequalification requirements for international procurement
- Validated cold-chain distribution
- Tender qualification
- Reliable antigen supply
- Post-market surveillance
The strongest commercial risk to an incumbent is a low-cost, regulator-approved competitor with adequate supply. The strongest strategic risk is TCV substitution.
What licensing deals affect the market?
Large licensing transactions are more visible in TCV than in legacy Vi polysaccharide vaccines. The commercial model for Vi vaccine is generally based on direct manufacturing, local registration, distribution agreements and public procurement contracts.
Licensing can still matter for:
- Local fill-finish
- Regional packaging
- Technology transfer
- Government supply commitments
- Co-marketing in travel markets
The absence of a high-profile licensing transaction does not eliminate commercial value. It indicates that the product is sold through mature supply and distribution channels rather than through a platform-technology licensing model.
How strong is the patent estate for Vi polysaccharide vaccine?
The patent estate is weak as a long-term exclusivity tool and stronger as an operational barrier.
| Factor |
Assessment |
| Core antigen patent life |
Largely exhausted |
| Formulation patent strength |
Limited and product-specific |
| Method-of-use protection |
Limited |
| Manufacturing know-how |
Material |
| Regulatory barriers |
Material |
| Brand and distribution |
Material in travel markets |
| Litigation leverage |
Low |
| Biosimilar risk |
Not the principal issue |
| TCV substitution risk |
High |
Key Takeaways
- Typhoid Vi polysaccharide vaccine is a mature vaccine product with stable but narrowing demand.
- Sanofi’s Typhim Vi remains the leading branded travel-market product.
- TCV is the preferred product for routine immunization because it can be used in younger children and offers stronger expected durability.
- Product-specific standalone revenue is not publicly disclosed, and published market estimates often combine Vi vaccine with TCV and other typhoid products.
- The financial profile is likely stable-to-declining, with the best economics in private travel vaccination and the weakest margins in public tenders.
- Patent expiry is not the main competitive issue. Manufacturing validation, regulatory approvals, supply reliability and tender access matter more.
- Paragraph IV litigation and biosimilar competition are unlikely to define the category.
- The principal long-term risk is substitution by TCV, not generic entry.
- Vi vaccine retains value in travel clinics, outbreak response and markets where TCV access remains constrained.
FAQs
Is typhoid Vi polysaccharide vaccine still commercially viable?
Yes. It remains viable in travel medicine and selected public-health settings, but its growth potential is limited by TCV adoption.
Is Typhim Vi a biologic drug?
Yes. It is a biological vaccine product regulated as a vaccine rather than as a conventional small-molecule drug.
Does Vi polysaccharide vaccine have a biosimilar competitor?
Biosimilar terminology is not the primary framework. Competing vaccines generally require independent regulatory approval rather than approval through a standard biosimilar pathway.
Can Vi polysaccharide vaccine be used in infants?
Generally no. Typhim Vi is indicated for individuals aged two years and older, while some TCV products are approved for use from six months of age.[2]
What is the biggest investment risk in the Vi vaccine market?
The largest risk is long-term displacement by TCV in routine immunization, combined with price pressure from regional vaccine manufacturers.
References
-
World Health Organization. (2018). Typhoid vaccines: WHO position paper, March 2018. Weekly Epidemiological Record, 93(13), 153-172.
-
Sanofi Pasteur. (2023). Typhim Vi: Prescribing information. U.S. Food and Drug Administration.
-
Centers for Disease Control and Prevention. (2024). Typhoid and paratyphoid fever: Traveler’s health. U.S. Department of Health and Human Services.
-
Gavi, the Vaccine Alliance. (2023). Typhoid conjugate vaccine support and country introductions. Gavi.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
